Toshifumi Sugatani
Overview
Explore the profile of Toshifumi Sugatani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1038
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee S, Fontana F, Sugatani T, Portales Castillo I, Leanza G, Coler-Reilly A, et al.
JCI Insight
. 2024 Feb;
9(6).
PMID: 38349739
Connexin43 (Cx43) is the most abundant gap junction protein present in the mesenchymal lineage. In mature adipocytes, Cx43 mediates white adipose tissue (WAT) beiging in response to cold exposure and...
2.
Lee S, Fontana F, Sugatani T, Portales Castillo I, Leanza G, Coler-Reilly A, et al.
bioRxiv
. 2024 Jan;
PMID: 38260624
Connexin43 (Cx43) is the most abundant gap junction protein present in the mesenchymal lineage. In mature adipocytes, Cx43 mediates white adipose tissue (WAT) "beiging" in response to cold exposure and...
3.
Sugatani T
Int J Mol Sci
. 2018 Aug;
19(9).
PMID: 30142896
The high cardiovascular mortality associated with chronic kidney disease (CKD) is caused in part by the CKD-mineral bone disorder (CKD-MBD) syndrome. The CKD-MBD consists of skeletal, vascular and cardiac pathology...
4.
Williams M, Sugatani T, Agapova O, Fang Y, Gaut J, Faugere M, et al.
Kidney Int
. 2017 Aug;
93(1):147-158.
PMID: 28843411
We examined activin receptor type IIA (ActRIIA) activation in chronic kidney disease (CKD) by signal analysis and inhibition in mice with Alport syndrome using the ActRIIA ligand trap RAP-011 initiated...
5.
Hruska K, Sugatani T, Agapova O, Fang Y
Bone
. 2017 Jan;
100:80-86.
PMID: 28119179
The causes of excess cardiovascular mortality associated with chronic kidney disease (CKD) have been attributed in part to the CKD-mineral bone disorder syndrome (CKD-MBD), wherein, novel cardiovascular risk factors have...
6.
Sugatani T, Agapova O, Fang Y, Berman A, Wallace J, Malluche H, et al.
Kidney Int
. 2016 Sep;
91(1):86-95.
PMID: 27666759
Dysregulation of skeletal remodeling is a component of renal osteodystrophy. Previously, we showed that activin receptor signaling is differentially affected in various tissues in chronic kidney disease (CKD). We tested...
7.
Agapova O, Fang Y, Sugatani T, Seifert M, Hruska K
Kidney Int
. 2016 May;
89(6):1231-43.
PMID: 27165838
The causes of cardiovascular mortality associated with chronic kidney disease (CKD) are partly attributed to the CKD-mineral bone disorder (CKD-MBD). The causes of the early CKD-MBD are not well known....
8.
Hruska K, Mathew S, Lund R, Fang Y, Sugatani T
Kidney Int
. 2016 Jan;
79121:S9-S13.
PMID: 26746860
Risk factors for disease states are rigorously defined. This analysis considers the definition of a risk factor as applied to the question of whether the serum phosphorus level is a...
9.
Sugatani T, Agapova O, Malluche H, Hruska K
Bone
. 2015 Jul;
81:168-177.
PMID: 26189760
Deficiency of Sirtuin 6 (SIRT6), a chromatin-related deacetylase, in mice reveals severe premature aging phenotypes including osteopenia. However, the underlying molecular mechanisms of SIRT6 in bone metabolism are unknown. Here...
10.
Hruska K, Seifert M, Sugatani T
Curr Opin Nephrol Hypertens
. 2015 Jun;
24(4):303-9.
PMID: 26050115
Purpose Of Review: The causes of excess cardiovascular mortality associated with chronic kidney disease (CKD) have been attributed in part to the CKD-mineral bone disorder syndrome (CKD-MBD), wherein, novel cardiovascular...